23948sdkhjf
Köp Köp åtkomst
  • {{ window.visitor.ipAccess.corporateClient.name }}

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
  • {{ window.visitor.ipAccess.corporateClient.name }}

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
News in English

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by an extensive Scandinavian study.

GLP-1 analogues, such as Ozempic, lower blood sugar levels, slow stomach digestion, and suppress appetite. However, some previous studies and side effect data have indicated that the drugs may be linked to an increased risk of thyroid tumours.

Researchers at the Karolinska Institute, among others, have now investigated the matter by analysing national registry data from Sweden, Denmark and Norway for around 145,000 patients treated with GLP-1 analogues and 290,000 patients treated with another type of diabetes drug, DPP4 inhibitors.

BREAKING
{{ article.headline }}
0.156